Logo image of TEVA

TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis

NYSE:TEVA - New York Stock Exchange, Inc. - US8816242098 - ADR - Currency: USD

16.74  -0.26 (-1.53%)

After market: 16.7505 +0.01 (+0.06%)

Fundamental Rating

4

Overall TEVA gets a fundamental rating of 4 out of 10. We evaluated TEVA against 194 industry peers in the Pharmaceuticals industry. While TEVA is still in line with the averages on profitability rating, there are concerns on its financial health. TEVA is valued quite cheap, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year TEVA was profitable.
TEVA had a positive operating cash flow in the past year.
In the past 5 years TEVA reported 4 times negative net income.
Of the past 5 years TEVA 4 years had a positive operating cash flow.
TEVA Yearly Net Income VS EBIT VS OCF VS FCFTEVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5B -5B -10B -15B

1.2 Ratios

With an excellent Return On Assets value of -1.15%, TEVA belongs to the best of the industry, outperforming 80.54% of the companies in the same industry.
The Return On Equity of TEVA (-7.49%) is better than 78.38% of its industry peers.
With an excellent Return On Invested Capital value of 10.36%, TEVA belongs to the best of the industry, outperforming 88.11% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for TEVA is significantly below the industry average of 44.04%.
The 3 year average ROIC (8.01%) for TEVA is below the current ROIC(10.36%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -1.15%
ROE -7.49%
ROIC 10.36%
ROA(3y)-1.99%
ROA(5y)-3.12%
ROE(3y)-11.58%
ROE(5y)-16.34%
ROIC(3y)8.01%
ROIC(5y)7.1%
TEVA Yearly ROA, ROE, ROICTEVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80

1.3 Margins

Looking at the Operating Margin, with a value of 22.79%, TEVA belongs to the top of the industry, outperforming 88.11% of the companies in the same industry.
TEVA's Operating Margin has improved in the last couple of years.
TEVA has a Gross Margin of 50.74%. This is in the better half of the industry: TEVA outperforms 61.62% of its industry peers.
TEVA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 22.79%
PM (TTM) N/A
GM 50.74%
OM growth 3Y5.53%
OM growth 5Y5.95%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.49%
GM growth 5Y2.73%
TEVA Yearly Profit, Operating, Gross MarginsTEVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

TEVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
There is no outstanding debt for TEVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TEVA Yearly Shares OutstandingTEVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B
TEVA Yearly Total Debt VS Total AssetsTEVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20B 40B 60B 80B

2.2 Solvency

Based on the Altman-Z score of 0.49, we must say that TEVA is in the distress zone and has some risk of bankruptcy.
TEVA has a Altman-Z score (0.49) which is comparable to the rest of the industry.
TEVA has a debt to FCF ratio of 27.45. This is a negative value and a sign of low solvency as TEVA would need 27.45 years to pay back of all of its debts.
TEVA has a better Debt to FCF ratio (27.45) than 79.46% of its industry peers.
TEVA has a Debt/Equity ratio of 2.61. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.61, TEVA is doing worse than 81.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF 27.45
Altman-Z 0.49
ROIC/WACC1.44
WACC7.2%
TEVA Yearly LT Debt VS Equity VS FCFTEVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B

2.3 Liquidity

TEVA has a Current Ratio of 0.89. This is a bad value and indicates that TEVA is not financially healthy enough and could expect problems in meeting its short term obligations.
TEVA has a worse Current ratio (0.89) than 89.19% of its industry peers.
A Quick Ratio of 0.59 indicates that TEVA may have some problems paying its short term obligations.
TEVA has a Quick ratio of 0.59. This is amonst the worse of the industry: TEVA underperforms 92.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.59
TEVA Yearly Current Assets VS Current LiabilitesTEVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B

More info and screens

2

3. Growth

3.1 Past

The earnings per share for TEVA have decreased by -2.73% in the last year.
Measured over the past years, TEVA shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.18% on average per year.
EPS 1Y (TTM)-2.73%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%-29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-5.12%

3.2 Future

TEVA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.39% yearly.
Based on estimates for the next years, TEVA will show a small growth in Revenue. The Revenue will grow by 2.80% on average per year.
EPS Next Y12.87%
EPS Next 2Y8.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.46%
Revenue Next 2Y2.8%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
TEVA Yearly Revenue VS EstimatesTEVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5B 10B 15B 20B
TEVA Yearly EPS VS EstimatesTEVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 6.72 indicates a rather cheap valuation of TEVA.
Based on the Price/Earnings ratio, TEVA is valued cheaply inside the industry as 96.22% of the companies are valued more expensively.
TEVA is valuated cheaply when we compare the Price/Earnings ratio to 29.63, which is the current average of the S&P500 Index.
TEVA is valuated cheaply with a Price/Forward Earnings ratio of 5.96.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 95.14% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, TEVA is valued rather cheaply.
Industry RankSector Rank
PE 6.72
Fwd PE 5.96
TEVA Price Earnings VS Forward Price EarningsTEVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

91.35% of the companies in the same industry are more expensive than TEVA, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, TEVA is valued cheaply inside the industry as 83.78% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 27.93
EV/EBITDA 7.43
TEVA Per share dataTEVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of TEVA may justify a higher PE ratio.
PEG (NY)0.52
PEG (5Y)N/A
EPS Next 2Y8.39%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TEVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TEVA PHARMACEUTICAL-SP ADR

NYSE:TEVA (2/21/2025, 8:04:00 PM)

After market: 16.7505 +0.01 (+0.06%)

16.74

-0.26 (-1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-29 2025-01-29/dmh
Earnings (Next)05-06 2025-05-06/bmo
Inst Owners6.89%
Inst Owner Change4.47%
Ins Owners0.54%
Ins Owner Change-1.92%
Market Cap18.97B
Analysts42.22
Price Target0.07 (-99.58%)
Short Float %1.98%
Short Ratio1.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.03%
Min EPS beat(2)-8.98%
Max EPS beat(2)4.92%
EPS beat(4)2
Avg EPS beat(4)5.71%
Min EPS beat(4)-8.98%
Max EPS beat(4)28.49%
EPS beat(8)3
Avg EPS beat(8)-2.49%
EPS beat(12)5
Avg EPS beat(12)-2.1%
EPS beat(16)7
Avg EPS beat(16)-1.87%
Revenue beat(2)1
Avg Revenue beat(2)0.22%
Min Revenue beat(2)-0.39%
Max Revenue beat(2)0.82%
Revenue beat(4)3
Avg Revenue beat(4)2.83%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)9.4%
Revenue beat(8)4
Avg Revenue beat(8)0.19%
Revenue beat(12)4
Avg Revenue beat(12)-1.75%
Revenue beat(16)5
Avg Revenue beat(16)-2.14%
PT rev (1m)22.64%
PT rev (3m)30.95%
EPS NQ rev (1m)-0.01%
EPS NQ rev (3m)-0.01%
EPS NY rev (1m)1.35%
EPS NY rev (3m)1.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1%
Valuation
Industry RankSector Rank
PE 6.72
Fwd PE 5.96
P/S 1.16
P/FCF 27.93
P/OCF 16.24
P/B 2.98
P/tB N/A
EV/EBITDA 7.43
EPS(TTM)2.49
EY14.87%
EPS(NY)2.81
Fwd EY16.79%
FCF(TTM)0.6
FCFY3.58%
OCF(TTM)1.03
OCFY6.16%
SpS14.38
BVpS5.61
TBVpS-13.22
PEG (NY)0.52
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.15%
ROE -7.49%
ROCE 13.12%
ROIC 10.36%
ROICexc 11.25%
ROICexgc 62.08%
OM 22.79%
PM (TTM) N/A
GM 50.74%
FCFM 4.17%
ROA(3y)-1.99%
ROA(5y)-3.12%
ROE(3y)-11.58%
ROE(5y)-16.34%
ROIC(3y)8.01%
ROIC(5y)7.1%
ROICexc(3y)8.75%
ROICexc(5y)7.67%
ROICexgc(3y)44.24%
ROICexgc(5y)41.47%
ROCE(3y)10.15%
ROCE(5y)9.04%
ROICexcg growth 3Y8.62%
ROICexcg growth 5Y4.84%
ROICexc growth 3Y12.61%
ROICexc growth 5Y12.54%
OM growth 3Y5.53%
OM growth 5Y5.95%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.49%
GM growth 5Y2.73%
F-Score6
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF 27.45
Debt/EBITDA 3.46
Cap/Depr 45.28%
Cap/Sales 3%
Interest Coverage 250
Cash Conversion 24.37%
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.59
Altman-Z 0.49
F-Score6
WACC7.2%
ROIC/WACC1.44
Cap/Depr(3y)43.26%
Cap/Depr(5y)39.48%
Cap/Sales(3y)3.51%
Cap/Sales(5y)3.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.73%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%-29%
EPS Next Y12.87%
EPS Next 2Y8.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-5.12%
Revenue Next Year4.46%
Revenue Next 2Y2.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.2%
EBIT growth 3Y3.78%
EBIT growth 5Y2.33%
EBIT Next Year27.4%
EBIT Next 3Y12.39%
EBIT Next 5YN/A
FCF growth 1Y42.95%
FCF growth 3Y9.69%
FCF growth 5Y-14.05%
OCF growth 1Y10.4%
OCF growth 3Y4%
OCF growth 5Y-10.97%